Alzheimer's disease - imaging test

Professor Donna Wilcock discusses a new biological technique for diagnosing Alzheimer's disease using PET neuroimaging.

There are some imaging mechanisms that are coming up that use injectable compounds that will readily cross into the brain and bind to amyloid plaques. We can see this on (typically) PET scanning, which will give you an image of the brain. Basically, different colors will tell you how much amyloid is in that part of the brain. These are looking really promising and it’s still in very late stage clinical trials – they call it the PiB compound. This is very late stage clinical trials but should be coming into the clinic, I believe, reasonably soon. It is safe. The biggest question is reproducibility – if you see the same patient over many different times, do you see the same levels of amyloid? I think that is going to have to be used in conjunction with the battery of memory tests. Really only, a true, true diagnosis of Alzheimer’s disease is only made at autopsy when we see the amyloid plaques, the tangles, and the neurodegeneration, the neuron loss.

alzheimer, diagnosis, imaging, scanning, neuroimaging, pib, compound, neurodegeneration, tangle, pet, donna, wilcock

Related Content

800. Imaging Alzheimer's Disease

Neuroimaging techniques help scientists visualize Alzheimer's disease before the disease becomes debilitating.

  • ID: 800
  • Source: G2C

2174. Neuron loss

Professor Donna Wilcock describes how neurofibrillary tangles choke neurons, causing them to die. This is one of three hallmarks of Alzheimer's disease.

  • ID: 2174
  • Source: G2C

2227. Alzheimer's disease

An overview of Alzheimer's disease-related content on Genes to Cognition Online.

  • ID: 2227
  • Source: G2C

2186. Alzheimer's disease - clinical testing

Professor Donna Wilcock explains that Alzheimer's disease is diagnosed clinically by a battery of tests that can take a full day to administer.

  • ID: 2186
  • Source: G2C

2175. Alzheimer's disease medications - Aricept

Professor Donna Wilcock explains that Aricept can only provide short-term benefit in treating Alzheimer's disease.

  • ID: 2175
  • Source: G2C

2173. Neurofibrillary tangles

Professor Donna Wilcock describes neurofibrillary tangles, which form inside the neuron in Alzheimer's disease and are composed of tau proteins.

  • ID: 2173
  • Source: G2C

1153. Functional Magnetic Resonance Imaging (fMRI)

Professor Trevor Robbins describes functional magnetic resonance imaging (fMRI) technology, which is used to take detailed images of the functioning brain.

  • ID: 1153
  • Source: G2C

2026. Testing for Alzheimer’s disease

Professor Kenneth Kosik explains that Alzheimer's disease is traditionally diagnosed by a physician taking a history and physical. In the near future, neuroimaging will provide an accurate diagnosis.

  • ID: 2026
  • Source: G2C

2004. Neuroimaging - notes of caution

Doctor Thomas Insel points out that although neuroimaging is a tremendously exciting technique, there are no examples of findings affecting clinical practice or diagnosis.

  • ID: 2004
  • Source: G2C

2188. Early-onset Alzheimer's disease, 30-65

Professor Donna Wilcock discusses early-onset Alzheimer's disease, which can reach an advanced stage by the age of 50 or 60 years.

  • ID: 2188
  • Source: G2C